Research Library › GHRH & Ghrelin-Receptor
GHRP-6 (growth hormone-releasing peptide-6) is a synthetic hexapeptide, six amino acids long with two in the mirror-image D form, designed to act at the growth hormone secretagogue receptor. It was reported in 1984 by Cyril Bowers and colleagues, including Frank Momany, at Tulane University in New Orleans, and became the founding member of the GHRP family. As of 22 Oct 2026 it is not FDA-approved and is on FDA’s Category 2 list for compounding.
Key facts
| Type | Synthetic 6-amino-acid peptide (hexapeptide) containing two D-amino acids |
|---|---|
| Derived from | Synthetic enkephalin analogs; no natural counterpart |
| First described | 1984, Cyril Bowers and colleagues, Tulane University |
| Developed by | Cyril Y. Bowers (Tulane University, New Orleans) with Frank Momany and others |
| Designed target | Growth hormone secretagogue (ghrelin) receptor on the pituitary |
| Regulatory status (Oct 2026) | Not FDA-approved; FDA Category 2 since 2023; named on WADA 2026 list (S2) |
Who developed it
GHRP-6 came from the laboratory of endocrinologist Cyril Y. Bowers at Tulane University Medical School in New Orleans. In 1984 Bowers and colleagues, including the computational chemist Frank Momany, reported the hexapeptide [1][2]. Later relatives, including GHRP-2 and hexarelin, followed from the same line of work [2].
The numbering reflects the program’s sequence of synthetic candidates rather than any natural series. Its 1984 report came about 15 years before the receptor’s natural ligand, ghrelin, was identified [2][3].
What it was designed to target
The project began with synthetic analogs of enkephalin, a natural opioid peptide, after Bowers noticed that some of them caused pituitary cells to release growth hormone [2]. GHRP-6 is six amino acids long, and two of them are D-amino acids, the mirror-image form rarely used in natural proteins. Bowers described the GHRPs as being “of unnatural origin” [1][2].
GHRP-6 is designed to bind the growth hormone secretagogue receptor (GHS-R) on the pituitary. For roughly 15 years that receptor’s natural ligand was unknown; in 1999 a Japanese team identified it as ghrelin, a 28-amino-acid hormone made in the stomach [3].
Why it was created
The GHRPs acted on growth hormone release through a route separate from GHRH. Bowers saw them as research tools for studying and testing growth hormone regulation, and as evidence of a hormone that had not yet been found [1]. In a 1998 review he wrote that GHRP mirrors “a new natural hypothalamic hormone yet to be isolated”; ghrelin was reported the following year [1][3].
Later research also examined the GHRPs in cardiac models. For GHRP-6, that work was mostly in animals [2].
Research timeline
- 1984: Bowers’ team at Tulane reports GHRP-6 [2].
- 1998: Bowers predicts an undiscovered natural hormone acting through the same receptor [1].
- 1999: Ghrelin is identified in the stomach as that receptor’s natural ligand [3].
- 2017: A historical review of GHRP research, including cardiac studies, is published [2].
- 2023: FDA places GHRP-6 in Category 2 for compounding [4].
Regulatory status as of October 2026
As of 22 Oct 2026, GHRP-6 is not FDA-approved and has no approval elsewhere that we identified. In 2023 FDA placed it in Category 2 for outsourcing facilities, citing reports of serious adverse events and effects on cortisol and blood glucose [4]. It was not among the 12 peptides removed from Category 2 in April 2026 [5], nor among the seven peptides FDA advisers voted on in July 2026 [6].
GHRP-6 is covered by the 2026 World Anti-Doping Agency Prohibited List under S2 as a growth hormone-releasing peptide, prohibited at all times [7].
Available from Kalibra Labs
Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.
Frequently asked questions
Who discovered GHRP-6?
GHRP-6 was reported in 1984 by Cyril Bowers and colleagues, including Frank Momany, at Tulane University in New Orleans.
Is GHRP-6 FDA approved?
No. As of 22 Oct 2026 GHRP-6 is not FDA-approved, and FDA has listed it in Category 2 for compounding since 2023.
What receptor does GHRP-6 target?
It is designed to bind the growth hormone secretagogue receptor, whose natural ligand, ghrelin, was identified in 1999.
How is GHRP-6 related to ghrelin?
GHRP-6 was made before ghrelin was known. Its receptor had no identified natural ligand until 1999, when ghrelin was found in the stomach.
Sources
- Bowers CY (Tulane University Medical School, New Orleans). Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. 1998;54(12):1316–1329. doi:10.1007/s000180050257. Link
- Berlanga-Acosta J, Abreu-Cruz A, García-del Barco Herrera D, et al. Synthetic growth hormone-releasing peptides (GHRPs): a historical appraisal of the evidences supporting their cytoprotective effects. Clin Med Insights Cardiol. 2017;11:1179546817694558. doi:10.1177/1179546817694558. Link
- Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999 Dec 9;402:656–660. doi:10.1038/45230. Link
- U.S. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 list), content current as of 22 Apr 2026. Link
- Faviero GF, Asebey EJ (Frier Levitt). FDA to remove 12 popular peptides from the Category 2 “do not compound” list. 16 Apr 2026. Link
- Moeller M. FDA Advisory Committee recommends adding six of seven peptides to compounding list. American Med Spa Association, 24 Jul 2026. Link
- World Anti-Doping Agency. 2026 Prohibited List, S2.2.4 (GHRH and its analogues; growth hormone secretagogues; GH-releasing peptides). Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.
